B

    Biomea Fusion Inc (BMEA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.68
    -0.05 (-2.89%)

    Market Cap: $125.08M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(11/22)
    Avg Surprise
    -13.46%
    Streak
    5 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.22
    Range$-0.28 - $-0.17
    4 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.26-18.5%
    60d ago$-0.27-22.8%
    30d ago$-0.27-22.8%
    7d ago$-0.22+0.0%
    Current$-0.22
    Revenue Consensus
    $0
    Range$0 - $0
    7 analysts
    Dec 31, 2026
    EPS Consensus$-0.20
    Range$-0.40 - $0.00
    4 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.20---
    Sep 26EST
    		-$-0.22---
    Jun 26
    		$-0.12$-0.21+42.86%Beat+76.5%
    Mar 26
    		$-0.17$-0.19+10.53%Beat+78.8%
    Dec 25
    		$-0.12$-0.22+45.61%Beat+85.3%
    Sep 25
    		$-0.24$-0.29+17.24%Beat+73.6%
    Jun 25
    		$-0.51$-0.51+0.00%Beat+50.5%
    Mar 25
    		$-0.80$-0.60-33.33%Miss+26.6%
    Dec 24
    		$-0.81$-0.91+11.18%Beat+17.3%
    Sep 24
    		$-0.91$-0.91+0.00%Beat-13.7%
    Jun 24
    		$-1.03$-1.09+5.50%Beat-47.1%
    Mar 24
    		$-1.09$-0.93-17.20%Miss-11.2%
    Dec 23
    		$-0.98$-0.85-15.29%Miss-14.0%
    Sep 23
    		$-0.80$-0.83+3.61%Beat-2.6%
    Jun 23
    		$-0.70$-0.88+20.45%Beat-18.6%
    Mar 23
    		$-0.98$-0.81-20.99%Miss-75.0%
    Dec 22
    		$-0.86$-0.81-6.17%Miss-68.6%
    Sep 22
    		$-0.78$-0.64-21.88%Miss-81.4%
    Jun 22
    		$-0.59$-0.61+3.28%Beat-78.8%
    Mar 22
    		$-0.56$-0.53-5.66%Miss-14.3%
    Dec 21
    		$-0.51$-0.45-13.33%Miss-
    Sep 21
    		$-0.43$-0.40-7.50%Miss-
    Jun 21
    		$-0.33$-0.20-65.00%Miss-
    Mar 21
    		$-0.49$-0.14-250.00%Miss-

    Key Metrics

    Valuation
    P/E Ratio-2.59EV/EBITDA-3.75x
    Price/FCF-2.58xFCF Yield-38.82%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-164.10%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio3.47xQuick Ratio3.47x
    Trading Statistics
    Beta-0.30Avg Volume1.50M
    52-Week High$2.9952-Week Low$0.87

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.56
    SMA 20$1.42
    SMA 50$1.34
    SMA 200$1.36
    EMA 10$1.58
    EMA 20$1.48
    EMA 50$1.39
    EMA 200$1.46

    MACD

    Line: 0.11Signal: 0.07Hist: 0.04

    ADX

    ADX: 31.3+DI: 31.4-DI: 6.3

    Aroon & PSAR

    Aroon Up92.0
    Aroon Down20.0
    PSAR$1.54

    Bollinger Bands

    Upper Band$1.79
    Lower Band$1.05
    %B Position5262%(Upper)
    Band Width0.85

    RSI (14-Day)

    Overbought
    71.3

    Momentum Oscillators

    Stoch %K74.5
    Stoch %D77.3
    Williams %R-28.8
    ROC (10d)24.4%
    Momentum0.33
    CCI (20d)118.0
    MFI (14d)93.2

    Volatility Measures

    ATR (14d)$0.11(6.8%)
    StdDev (20d)0.19
    Hist Vol67.2%(High)

    Volume Flow

    VWAP$1.72
    OBV56.1M
    AD Line12.2M
    CMF (20d)-0.142

    Volume Metrics

    Avg Vol (20d)1.5M
    Vol Ratio0.7x
    VWMA (20d)$1.57

    Pivot Points

    R3$1.86
    R2$1.80
    R1$1.77
    Pivot Point$1.71
    S1$1.67
    S2$1.61
    S3$1.58

    Advanced Oscillators

    TSI43.64
    Ultimate Osc46.0
    KST194.02

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$1.22M$0$0$0$6.14M$0
    Cost of Revenue$0$0$47,000$0$0$0N/A$0$0$0$1.13M$0
    Gross Profit$0$0$-47,000$0$0$0$1.22M$0$0$0$5.01M$0
    Operating Expenses$12.77M$12.77M$11.72M$20.80M$21.28M$29.71M$30.07M$34.04M$38.90M$41.06M$37.33M$31.12M
    R&D$9.14M$9.12M$8.12M$14.40M$16.57M$22.90M$25.24M$27.24M$31.82M$33.78M$30.87M$25.35M
    SG&A$3.62M$3.65M$3.60M$4.20M$4.71M$6.82M$4.83M$6.79M$7.07M$7.28M$6.46M$5.77M
    Operating Income$-12,766,000$-12,774,000$-11,719,000$-20,805,000$-21,276,000$-29,712,000$-30,074,000$-34,039,000$-38,898,000$-41,059,000$-37,328,000$-31,119,000
    Interest Income$319,000$430,000$-3,526,000$4.40M$309,000$450,000$772,000$1.25M$1.62M$2.00M$2.44M$2.69M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-12,447,000$-12,344,000$4.61M$-16,407,000$-20,967,000$-29,262,000$-29,302,000$-32,787,000$-37,276,000$-39,061,000$-34,884,000$-28,429,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-12,447,000$-12,344,000$4.61M$-16,407,000$-20,967,000$-29,262,000$-29,302,000$-32,787,000$-37,276,000$-39,061,000$-34,884,000$-28,429,000
    EBITDA$-12,700,000$-12,774,000$-11,672,000$-20,378,000$-20,018,000$-28,478,000$-29,605,000$-33,603,000$-39,474,000$-39,640,000$-36,908,000$-30,700,000
    EBIT$-12,766,000$-12,774,000$-11,719,000$-20,805,000$-21,276,000$-29,712,000$-30,074,000$-34,039,000$-38,898,000$-41,059,000$-37,328,000$-31,119,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about BMEA

    News

    Here's Why We're Watching Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation

    Biomea Fusion (NASDAQ:BMEA) is under scrutiny due to its high cash burn rate, having spent US$47m in the last year with cash reserves of US$35m, resulting in a short cash runway of about 9 months. While the company reduced its cash burn by 53% over the past year, its market capitalization of US$99m means that raising additional capital through share issuance could lead to significant shareholder dilution. The article advises caution for current shareholders, recommending close monitoring of the company's financial situation.

    Simply Wall Street•8/25/26•
    Bearish

    Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes

    Biomea Fusion, Inc. has completed enrollment for its COVALENT-211 Phase II clinical trial, evaluating icovamenib in patients with insulin-deficient Type 2 Diabetes (T2D) who are inadequately controlled by standard therapies. Topline data for this trial's primary endpoint are expected in Q1 2027, while enrollment for a second Phase II trial, COVALENT-212, targeting T2D patients not achieving glycemic targets despite GLP-1 based therapy, is ongoing with data anticipated in Q2 2027. Icovamenib is an orally administered investigational small molecule aiming to restore beta-cell function and provide durable glycemic control by downmodulating menin.

    Investing News Network•8/24/26•
    Bullish

    H.C. Wainwright reiterates Biomea Fusion stock rating on trial enrollment

    H.C. Wainwright has reiterated a Buy rating and a $4.00 price target for Biomea Fusion Inc. (NASDAQ:BMEA) after the company completed enrollment in its Phase 2 COVALENT-211 diabetes trial. The biotech firm, currently trading at $1.68 with a market cap of $121 million, anticipates topline 26-week data from this trial in Q1 2027. Additionally, Biomea Fusion is collaborating with the University of Leicester to study icovamenib in combination with semaglutide for weight management.

    Investing.com•8/24/26•
    Somewhat-Bullish

    Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes

    Biomea Fusion has announced the completion of enrollment for its COVALENT-211 Phase II clinical trial, evaluating icovamenib in patients with insulin-deficient Type 2 Diabetes (T2D). Topline 26-week data from COVALENT-211 is expected in the first quarter of 2027, with COVALENT-212, targeting a different T2D population, also nearing completion and expected to report data in Q2 2027. The trials build on previous findings that showed icovamenib's potential to restore beta-cell function and provide durable glycemic control.

    Yahoo Finance•8/24/26•
    Somewhat-Bullish

    Biomea Fusion (NASDAQ:BMEA) Gains Attention As Institutions Expand Exposure

    Biomea Fusion (NASDAQ:BMEA) is attracting renewed market interest due to increased institutional investment. The company, a clinical-stage biopharmaceutical firm focusing on precision therapies for cancer and metabolic diseases, sees its outlook driven by clinical execution, regulatory progress, and financial management. Its strategy centers on developing small-molecule treatments, with menin inhibition being a key area of scientific focus.

    Kalkine Media•8/14/26•
    Somewhat-Bullish

    Frequently Asked Questions About BMEA

    Does BMEA pay dividends?
    Biomea Fusion Inc (BMEA) does not currently pay a regular dividend.
    What is BMEA's market cap?
    Biomea Fusion Inc (BMEA) has a market capitalization of $125.08M with a current stock price of $1.68.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In